메뉴 건너뛰기




Volumn 67, Issue 2, 2010, Pages 160-165

COX-2 specific inhibitors enhance the cytotoxic effects of pemetrexed in mesothelioma cell lines

Author keywords

Cisplatin; COX 2; Cytotoxicity; Mesothelioma; Pemetrexed; Vinorelbine

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; 5 BROMO 2 (4 FLUOROPHENYL) 3 (4 METHYLSULFONYLPHENYL)THIOPHENE; CISPLATIN; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; FLURBIPROFEN; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NAVELBINE; PEMETREXED; SULINDAC;

EID: 72449176844     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2009.04.008     Document Type: Article
Times cited : (29)

References (36)
  • 1
    • 0842330312 scopus 로고    scopus 로고
    • Radical surgery for mesothelioma
    • Treasure T., Waller D., Swift S., and Peto J. Radical surgery for mesothelioma. BMJ 328 (2004) 237-238
    • (2004) BMJ , vol.328 , pp. 237-238
    • Treasure, T.1    Waller, D.2    Swift, S.3    Peto, J.4
  • 2
    • 3142768949 scopus 로고    scopus 로고
    • Chemotherapy for malignant pleural mesothelioma: past results and recent developments
    • Tomek S., and Manegold C. Chemotherapy for malignant pleural mesothelioma: past results and recent developments. Lung Cancer 455 (2004) S103-S119
    • (2004) Lung Cancer , vol.455
    • Tomek, S.1    Manegold, C.2
  • 3
    • 33846327132 scopus 로고    scopus 로고
    • Lung Cancer Disease Site Group of Cancer Care Ontario's Program in evidence-based care. The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline
    • Ellis P., Davies A.M., Evans W.K., Haynes A.E., and Lloyd N.S. Lung Cancer Disease Site Group of Cancer Care Ontario's Program in evidence-based care. The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline. J Thorac Oncol 1 (2006) 591-601
    • (2006) J Thorac Oncol , vol.1 , pp. 591-601
    • Ellis, P.1    Davies, A.M.2    Evans, W.K.3    Haynes, A.E.4    Lloyd, N.S.5
  • 4
    • 46349091630 scopus 로고    scopus 로고
    • Current concepts in chemotherapy for malignant pleural mesothelioma
    • Sørensen J.B. Current concepts in chemotherapy for malignant pleural mesothelioma. Clin Respir J 2 (2008) 74-79
    • (2008) Clin Respir J , vol.2 , pp. 74-79
    • Sørensen, J.B.1
  • 5
    • 0036837690 scopus 로고    scopus 로고
    • Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature and meta-analysis
    • Berghmans T., Paesmans M., Lalami Y., Louviaux I., Luce S., Mascaux C., et al. Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature and meta-analysis. Lung Cancer 38 (2002) 111-121
    • (2002) Lung Cancer , vol.38 , pp. 111-121
    • Berghmans, T.1    Paesmans, M.2    Lalami, Y.3    Louviaux, I.4    Luce, S.5    Mascaux, C.6
  • 7
    • 46349111832 scopus 로고    scopus 로고
    • Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma
    • Sørensen J.B., Frank H., and Palshof T. Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma. Br J Cancer 99 (2008) 44-50
    • (2008) Br J Cancer , vol.99 , pp. 44-50
    • Sørensen, J.B.1    Frank, H.2    Palshof, T.3
  • 8
    • 0041629528 scopus 로고    scopus 로고
    • Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma
    • Vogelzang N.J., Rusthoven J.J., Symanowski J., Denham C., Kaukel E., Ruffie P., et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21 (2003) 2636-2644
    • (2003) J Clin Oncol , vol.21 , pp. 2636-2644
    • Vogelzang, N.J.1    Rusthoven, J.J.2    Symanowski, J.3    Denham, C.4    Kaukel, E.5    Ruffie, P.6
  • 9
    • 58149083475 scopus 로고    scopus 로고
    • Systemic treatments for mesothelioma: standard and novel
    • Kindler H.L. Systemic treatments for mesothelioma: standard and novel. Curr Treat Options Oncol 9 (2008) 171-179
    • (2008) Curr Treat Options Oncol , vol.9 , pp. 171-179
    • Kindler, H.L.1
  • 10
    • 3042575322 scopus 로고    scopus 로고
    • Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent
    • Adjei A.A. Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent. Clin Cancer Res 10 (2004) 4276s-4280s
    • (2004) Clin Cancer Res , vol.10
    • Adjei, A.A.1
  • 11
    • 20644466217 scopus 로고    scopus 로고
    • New agents in the management of advanced mesothelioma
    • Vogelzang N.J., Porta C., and Mutti L. New agents in the management of advanced mesothelioma. Semin Oncol 32 (2005) 336-350
    • (2005) Semin Oncol , vol.32 , pp. 336-350
    • Vogelzang, N.J.1    Porta, C.2    Mutti, L.3
  • 12
    • 0037842139 scopus 로고    scopus 로고
    • Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma
    • Scagliotti G.V., Shin D.M., Kindler H.L., Vasconcelles M.J., Keppler U., Manegold C., et al. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol 21 (2003) 1556-1561
    • (2003) J Clin Oncol , vol.21 , pp. 1556-1561
    • Scagliotti, G.V.1    Shin, D.M.2    Kindler, H.L.3    Vasconcelles, M.J.4    Keppler, U.5    Manegold, C.6
  • 13
    • 0034046032 scopus 로고    scopus 로고
    • An assessment of the antithymine and antipurine characteristics of MTA (LY 231514) in CCRF-CEM cells
    • Chen V.J., Bewley J.R., Smith P.G., Andis S.L., Schultz R.M., Iversen P.W., et al. An assessment of the antithymine and antipurine characteristics of MTA (LY 231514) in CCRF-CEM cells. Adv Enzyme Regul 40 (2000) 143-154
    • (2000) Adv Enzyme Regul , vol.40 , pp. 143-154
    • Chen, V.J.1    Bewley, J.R.2    Smith, P.G.3    Andis, S.L.4    Schultz, R.M.5    Iversen, P.W.6
  • 15
    • 0141963117 scopus 로고    scopus 로고
    • Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents?
    • Gasparini G., Longo R., Sarmiento R., and Morabito A. Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents?. Lancet Oncol 4 (2003) 605-615
    • (2003) Lancet Oncol , vol.4 , pp. 605-615
    • Gasparini, G.1    Longo, R.2    Sarmiento, R.3    Morabito, A.4
  • 16
    • 23844462448 scopus 로고    scopus 로고
    • Role of COX-2 selective inhibitors for prevention and treatment of cancer
    • Amir M., and Agarwal H.K. Role of COX-2 selective inhibitors for prevention and treatment of cancer. Pharmazie 60 (2005) 563-570
    • (2005) Pharmazie , vol.60 , pp. 563-570
    • Amir, M.1    Agarwal, H.K.2
  • 17
    • 27644555091 scopus 로고    scopus 로고
    • Cyclooxygenase-2: how good is it as a target for cancer chemoprevention?
    • Hull M.A. Cyclooxygenase-2: how good is it as a target for cancer chemoprevention?. Eur J Cancer 41 (2005) 1854-1863
    • (2005) Eur J Cancer , vol.41 , pp. 1854-1863
    • Hull, M.A.1
  • 18
    • 0034026144 scopus 로고    scopus 로고
    • Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines
    • Hida T., Kozaki K., Muramatsu H., Masuda A., Shimizu S., Mitsudomi T., et al. Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clin Cancer Res 6 (2000) 2006-2011
    • (2000) Clin Cancer Res , vol.6 , pp. 2006-2011
    • Hida, T.1    Kozaki, K.2    Muramatsu, H.3    Masuda, A.4    Shimizu, S.5    Mitsudomi, T.6
  • 19
    • 0345549483 scopus 로고    scopus 로고
    • Cyclooxygenase-2 (COX-2) inhibitors sensitize tumor cells specifically to death receptor-induced apoptosis independently of COX-2 inhibition
    • Totzke G., Schulze-Osthoff K., and Janicke R.U. Cyclooxygenase-2 (COX-2) inhibitors sensitize tumor cells specifically to death receptor-induced apoptosis independently of COX-2 inhibition. Oncogene 22 (2003) 8021-8030
    • (2003) Oncogene , vol.22 , pp. 8021-8030
    • Totzke, G.1    Schulze-Osthoff, K.2    Janicke, R.U.3
  • 21
    • 2442467100 scopus 로고    scopus 로고
    • Prognostic significance of cyclooxygenase-2 (COX-2) and expression of cell cycle inhibitors p21 and p27 in human pleural malignant mesothelioma
    • Baldi A., Santini D., Vasaturo F., Santini M., Vicidomini G., Di Marino M.P., et al. Prognostic significance of cyclooxygenase-2 (COX-2) and expression of cell cycle inhibitors p21 and p27 in human pleural malignant mesothelioma. Thorax 59 (2004) 428-433
    • (2004) Thorax , vol.59 , pp. 428-433
    • Baldi, A.1    Santini, D.2    Vasaturo, F.3    Santini, M.4    Vicidomini, G.5    Di Marino, M.P.6
  • 22
    • 22144439371 scopus 로고    scopus 로고
    • Cyclooxygenase-2 predicts survival in malignant pleural mesothelioma
    • O'Kane S.L., Cawkwell L., Campbell A., and Lind M.J. Cyclooxygenase-2 predicts survival in malignant pleural mesothelioma. Eur J Cancer 41 (2005) 1645-1648
    • (2005) Eur J Cancer , vol.41 , pp. 1645-1648
    • O'Kane, S.L.1    Cawkwell, L.2    Campbell, A.3    Lind, M.J.4
  • 23
    • 1342330958 scopus 로고    scopus 로고
    • Preclinical evaluation of the nonsteroidal anti-inflammatory agent celecoxib on malignant mesothelioma chemoprevention
    • Catalano A., Graciotti L., Rinaldi, Raffaelli G., Rodilossi S., Betta P., et al. Preclinical evaluation of the nonsteroidal anti-inflammatory agent celecoxib on malignant mesothelioma chemoprevention. Int J Cancer 109 (2004) 322-328
    • (2004) Int J Cancer , vol.109 , pp. 322-328
    • Catalano, A.1    Graciotti, L.2    Rinaldi3    Raffaelli, G.4    Rodilossi, S.5    Betta, P.6
  • 24
    • 15044361542 scopus 로고    scopus 로고
    • Cyclooxygenase-2 protein levels are independent of epidermal growth factor receptor expression or activation in operable non-small cell lung cancer
    • Richardson C.M., Richardson D., Swinson D.E., Swain W.A., Cox G., and O'Byrne K.J. Cyclooxygenase-2 protein levels are independent of epidermal growth factor receptor expression or activation in operable non-small cell lung cancer. Lung Cancer 48 (2005) 47-57
    • (2005) Lung Cancer , vol.48 , pp. 47-57
    • Richardson, C.M.1    Richardson, D.2    Swinson, D.E.3    Swain, W.A.4    Cox, G.5    O'Byrne, K.J.6
  • 25
    • 27144467703 scopus 로고    scopus 로고
    • Radiosensitivity enhancement by celecoxib, a cyclooxygenase (COX)-2 selective inhibitor, via COX-2-dependent cell cycle regulation on human cancer cells expressing differential COX-2 levels
    • Shin Y.K., Park J.S., Kim H.S., Jun H.J., Kim G.E., Suh C.O., et al. Radiosensitivity enhancement by celecoxib, a cyclooxygenase (COX)-2 selective inhibitor, via COX-2-dependent cell cycle regulation on human cancer cells expressing differential COX-2 levels. Cancer Res 65 (2005) 9501-9509
    • (2005) Cancer Res , vol.65 , pp. 9501-9509
    • Shin, Y.K.1    Park, J.S.2    Kim, H.S.3    Jun, H.J.4    Kim, G.E.5    Suh, C.O.6
  • 28
    • 44949244913 scopus 로고    scopus 로고
    • Molecular analysis of the effects of piroxicam and cisplatin on mesothelioma cells growth and viability
    • Verdina A., Cardillo I., Nebbioso A., Galati R., Menegozzo S., Altucci L., et al. Molecular analysis of the effects of piroxicam and cisplatin on mesothelioma cells growth and viability. J Transl Med 6 (2008) 27
    • (2008) J Transl Med , vol.6 , pp. 27
    • Verdina, A.1    Cardillo, I.2    Nebbioso, A.3    Galati, R.4    Menegozzo, S.5    Altucci, L.6
  • 29
    • 33745238704 scopus 로고    scopus 로고
    • Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors
    • Grösch S., Maier T.J., Schiffmann S., and Geisslinger G. Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst 98 (2006) 736-747
    • (2006) J Natl Cancer Inst , vol.98 , pp. 736-747
    • Grösch, S.1    Maier, T.J.2    Schiffmann, S.3    Geisslinger, G.4
  • 30
    • 58149486385 scopus 로고    scopus 로고
    • NS-398, ibuprofen, and cyclooxygenase-2 RNA interference produce significantly different gene expression profiles in prostate cancer cells
    • John-Aryankalayil M., Palayoor S.T., Cerna D., Falduto M.T., Magnuson S.R., and Coleman C.N. NS-398, ibuprofen, and cyclooxygenase-2 RNA interference produce significantly different gene expression profiles in prostate cancer cells. Mol Cancer Ther 8 (2009) 261-273
    • (2009) Mol Cancer Ther , vol.8 , pp. 261-273
    • John-Aryankalayil, M.1    Palayoor, S.T.2    Cerna, D.3    Falduto, M.T.4    Magnuson, S.R.5    Coleman, C.N.6
  • 31
    • 38049041523 scopus 로고    scopus 로고
    • Dup-697, a specific COX-2 inhibitor, suppresses growth and induces apoptosis on K562 leukemia cells by cell-cycle arrest and caspase-8 activation.
    • Peng H.L., Zhang G.S., Liu J.H., Gong F.J., and Li R.J. Dup-697, a specific COX-2 inhibitor, suppresses growth and induces apoptosis on K562 leukemia cells by cell-cycle arrest and caspase-8 activation. Ann Hematol 87 (2008) 121-129
    • (2008) Ann Hematol , vol.87 , pp. 121-129
    • Peng, H.L.1    Zhang, G.S.2    Liu, J.H.3    Gong, F.J.4    Li, R.J.5
  • 32
    • 34548682769 scopus 로고    scopus 로고
    • Inhibition of COX-2 with NS-398 decreases colon cancer cell motility through blocking epidermal growth factor receptor transactivation: possibilities for combination therapy
    • Banu N., Buda A., Chell S., Elder D., Moorghen M., Paraskeva C., et al. Inhibition of COX-2 with NS-398 decreases colon cancer cell motility through blocking epidermal growth factor receptor transactivation: possibilities for combination therapy. Cell Prolif 40 (2007) 768-779
    • (2007) Cell Prolif , vol.40 , pp. 768-779
    • Banu, N.1    Buda, A.2    Chell, S.3    Elder, D.4    Moorghen, M.5    Paraskeva, C.6
  • 33
    • 49049094938 scopus 로고    scopus 로고
    • NS-398 enhances the efficacy of gemcitabine against lung adenocarcinoma through up-regulation of p21WAF1 and p27KIP1 protein
    • Chen X.J., Xiao W., Qu X., and Zhou S.Y. NS-398 enhances the efficacy of gemcitabine against lung adenocarcinoma through up-regulation of p21WAF1 and p27KIP1 protein. Neoplasma 55 (2008) 200-204
    • (2008) Neoplasma , vol.55 , pp. 200-204
    • Chen, X.J.1    Xiao, W.2    Qu, X.3    Zhou, S.Y.4
  • 34
    • 33144485911 scopus 로고    scopus 로고
    • COX-2 inhibitors suppress lung cancer cell growth by inducing p21 via COX-2 independent signals
    • Han S., and Roman J. COX-2 inhibitors suppress lung cancer cell growth by inducing p21 via COX-2 independent signals. Lung Cancer 51 (2006) 283-296
    • (2006) Lung Cancer , vol.51 , pp. 283-296
    • Han, S.1    Roman, J.2
  • 35
    • 42649093479 scopus 로고    scopus 로고
    • Mechanism of growth inhibitory effects of cyclooxygenase-2 inhibitor-NS398 on cancer cells
    • Li S., Tong Q., Zhang W., Wang Q., Chen Z., and Wu Q. Mechanism of growth inhibitory effects of cyclooxygenase-2 inhibitor-NS398 on cancer cells. Cancer Invest 26 (2008) 333-337
    • (2008) Cancer Invest , vol.26 , pp. 333-337
    • Li, S.1    Tong, Q.2    Zhang, W.3    Wang, Q.4    Chen, Z.5    Wu, Q.6
  • 36
    • 0037652020 scopus 로고    scopus 로고
    • The cyclooxygenase 2-selective inhibitor NS398 inhibits proliferation of oral carcinoma cell lines by mechanisms dependent and independent of reduced prostaglandin E2 synthesis
    • Minter H.A., Eveson J.W., Huntley S., Elder D.J., and Hague A. The cyclooxygenase 2-selective inhibitor NS398 inhibits proliferation of oral carcinoma cell lines by mechanisms dependent and independent of reduced prostaglandin E2 synthesis. Clin Cancer Res 9 (2003) 1885-1897
    • (2003) Clin Cancer Res , vol.9 , pp. 1885-1897
    • Minter, H.A.1    Eveson, J.W.2    Huntley, S.3    Elder, D.J.4    Hague, A.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.